Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/182734
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Martín-Broto, Javier | es_ES |
dc.contributor.author | Redondo, Andrés | es_ES |
dc.contributor.author | Valverde, Claudia M. | es_ES |
dc.contributor.author | Vaz Salgado, María Ángeles | es_ES |
dc.contributor.author | Mora, Jaume | es_ES |
dc.contributor.author | García del Muro, Xavier | es_ES |
dc.contributor.author | Gutiérrez, Antonio | es_ES |
dc.contributor.author | Tous, Cristina | es_ES |
dc.contributor.author | Carnero, Amancio | es_ES |
dc.contributor.author | Marcilla-Plaza, David | es_ES |
dc.contributor.author | Carranza Carranza, Andrés | es_ES |
dc.contributor.author | Sancho, Pilar | es_ES |
dc.contributor.author | Martínez-Trufero, Javier | es_ES |
dc.contributor.author | Díaz-Beveridge, Robert | es_ES |
dc.contributor.author | Cruz Jurado, Josefina | es_ES |
dc.contributor.author | Encinas-Tobajas, Víctor | es_ES |
dc.contributor.author | Taron Roca, Miguel | es_ES |
dc.contributor.author | Moura, David S. | es_ES |
dc.contributor.author | Luna, Pablo | es_ES |
dc.contributor.author | Hindi, Nadia | es_ES |
dc.contributor.author | López-Pousa, Antonio | es_ES |
dc.date.accessioned | 2019-05-29T09:16:59Z | - |
dc.date.available | 2019-05-29T09:16:59Z | - |
dc.date.issued | 2017-12 | - |
dc.identifier.citation | Annals of Oncology 28(12): 2994-2999 (2017) | es_ES |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | http://hdl.handle.net/10261/182734 | - |
dc.description.abstract | [Background] Patients with relapsed unresectable osteosarcoma represents an unmet need, so active and safe systemic treatments are required. Fas cell surface death receptor and mammalian target of rapamycin pathways are implicated in progressing osteosarcoma, and we had preclinical and clinical experience with a scheme that targets both pathways. Therefore, we designed a phase II trial with gemcitabine plus rapamycin, to determine the efficacy and safety, in this subset of patients. | es_ES |
dc.description.abstract | [Patients and methods] A multicenter, single-arm phase II trial was sponsored by the Spanish Group for Research on Sarcoma. Osteosarcoma patients, relapsed or progressing after standard chemotherapy and unsuitable for metastasectomy received gemcitabine and rapamycin p.o. 5 mg/day except for the same day of gemcitabine administration, and the day before. The main end point was 4-month progression-free survival rate (PFSR), with the assumption that rates higher than 40% would be considered as an active regimen. Translational research aimed to correlate biomarkers with the clinical outcome. | es_ES |
dc.description.abstract | [Results] Thirty-five patients were enrolled and received at least one cycle. PFSR at 4 months was 44%, and after central radiologic assessment, 2 partial responses and 14 stabilizations (48.5%) were reported from 33 assessable patients. The most frequent grade 3–4 adverse events were: neutropenia (37%), thrombocytopenia (20%), anemia (23%), and fatigue (15%); however, only three patients had febrile neutropenia. Positive protein expression of RRM1 significantly correlated with worse PFS and overall survival, while positivity of P-ERK1/2 was correlated with significant better overall survival. | es_ES |
dc.description.abstract | [Conclusion] Gemcitabine plus sirolimus exhibits satisfactory antitumor activity and safety in this osteosarcoma population, exceeding the prespecified 40% of 4-month PFSR. The significant correlation of biomarkers with clinical outcome encourages further prospective investigation. | es_ES |
dc.description.sponsorship | This work was funded by the Ministry of Health, Social Policy and Equality of Spain, through a public competitive call (project reference EC11-444) and by the Spanish Group for Research on Sarcoma (GEIS), which sponsored the trial (no grant numbers apply). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Oxford University Press | es_ES |
dc.rights | closedAccess | es_ES |
dc.subject | Osteosarcoma | es_ES |
dc.subject | Gemcitabine | es_ES |
dc.subject | Sirolimus | es_ES |
dc.subject | Second-line | es_ES |
dc.subject | Phase II | es_ES |
dc.subject | RRM1 | es_ES |
dc.title | Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS) | es_ES |
dc.type | artículo | es_ES |
dc.identifier.doi | 10.1093/annonc/mdx536 | - |
dc.description.peerreviewed | Peer reviewed | es_ES |
dc.relation.publisherversion | https://doi.org/10.1093/annonc/mdx536 | es_ES |
dc.identifier.e-issn | 1569-8041 | - |
dc.contributor.funder | Ministerio de Sanidad, Servicios Sociales e Igualdad (España) | es_ES |
dc.contributor.funder | Grupo Español de Investigación en Sarcomas | es_ES |
dc.relation.csic | Sí | es_ES |
oprm.item.hasRevision | no ko 0 false | * |
dc.identifier.funder | http://dx.doi.org/10.13039/501100003751 | es_ES |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.openairetype | artículo | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 59,24 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
45
checked on 09-abr-2024
WEB OF SCIENCETM
Citations
43
checked on 24-feb-2024
Page view(s)
253
checked on 19-abr-2024
Download(s)
46
checked on 19-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.